Ahmed Badran
Overview
Explore the profile of Ahmed Badran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
39
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Badran A, Ali S, Arabi T, Hinkston A, Shaik A, Elshenawy M, et al.
Clin Med Insights Case Rep
. 2023 Feb;
16:11795476231156290.
PMID: 36824292
Human epidermal growth factor receptor-positive breast cancer is an aggressive cancer which represents approximately a quarter of all breast cancers worldwide. Recent advances have led to the development of targeted...
12.
Alshamsan B, Aseafan M, Badran A, Shaheen A, Elshenawy M, Bazarbashi S, et al.
Mol Clin Oncol
. 2023 Feb;
18(3):17.
PMID: 36798464
Small bowel adenocarcinoma (SBA) is an extremely rare cancer type. In the present study, the patient characteristics and clinical outcomes of patients diagnosed and treated for SBA at a single...
13.
Bazarbashi S, Alzahrani A, Aljubran A, Elshenawy M, Gad A, Maraiki F, et al.
Oncologist
. 2023 Jan;
28(5):e254-e262.
PMID: 36648325
Background: Tyrosine kinase inhibitors remain a cornerstone in managing metastatic clear cell renal cell carcinoma (RCC). The 4 weeks on/2 weeks off intermittent sunitinib schedule could result in rebound angiogenesis...
14.
Alhusaini H, Elshenawy M, Badran A, Elshentenawy A, Mohieldin A, Gad A, et al.
Cureus
. 2022 Dec;
14(11):e31045.
PMID: 36475202
Objectives: Ovarian granulosa cell tumour is rare. This study aims to report the clinical characteristics and long-term outcomes of adult-type ovarian granulosa cell tumour (AOGCT) at King Faisal Specialist Hospital...
15.
Aljubran A, Badran A, Alrowaily M, Raef H, Alzahrani A, Almuhaideb A, et al.
Cancer Biother Radiopharm
. 2022 Nov;
39(2):164-168.
PMID: 36342790
Both everolimus and peptide receptor radionuclide therapy (PRRT) are approved as monotherapies for advanced neuroendocrine tumors (NETs). Research in animal models showed synergism between the two treatment modalities. This study...
16.
Bazarbashi S, Badran A, Gad A, Aljubran A, Alzahrani A, Alshibani A, et al.
Ann Surg Oncol
. 2022 Aug;
30(1):426-432.
PMID: 36042103
Background: The peritoneum frequently is the only recurrence site after radical resection of gastric cancer. Data suggest that hyperthermic intraperitoneal chemotherapy (HIPEC) and intraoperative radiotherapy (IORT) reduce peritoneal recurrence and...
17.
Bazarbashi S, Elshenawy M, Badran A, Aljubran A, Alzahrani A, Almanea H, et al.
Cancer Med
. 2022 Feb;
11(10):2056-2066.
PMID: 35146939
Introduction: Gemcitabine is a well-known radiosensitizer. Herein, we tested the efficacy and toxicity of preoperative concurrent infusional gemcitabine and radiotherapy in locally advanced rectal cancer. Patients And Methods: This was...
18.
Alshamsan B, Alshibany A, Elshenawy M, Badran A, Elhassan T, Ajarim D, et al.
Cancer Manag Res
. 2022 Jan;
13:9411-9420.
PMID: 35002318
Purpose: The correlation between the preoperative neutrophil-to-lymphocyte ratio (NLR) and Oncotype DX (ODX) recurrence score (RS) has not yet been established. We aimed to investigate the association between NLR and...
19.
Al-Tweigeri T, Elshenawy M, Badran A, Omar A, Suleman K, Al Malik O, et al.
J Oncol
. 2021 Feb;
2021:6639763.
PMID: 33628241
Purpose: This study was designed to examine the relationship between breast cancer molecular subtypes and pathological response to neoadjuvant chemotherapy (NAC) ± trastuzumab, in locally advanced breast cancer (LABC). Methods:...
20.
Elshenawy M, Badran A, Aljubran A, Alzahrani A, Rauf M, Eldali A, et al.
World J Surg Oncol
. 2020 Jul;
18(1):163.
PMID: 32641137
Background: Surgical resection of metastatic disease in patients with initially non-resectable colorectal cancer (CRC) has improved overall survival. Intensified chemotherapy regimens have increased the probability of converting unresectable metastasis to...